Glycosylation and NH2-terminal domain mutants of the tissue inhibitor of metalloproteinases-1 (TIMP-1)

Nancy C m Caterina, L. Windsor, M. Kirby Bodden, Audra E. Yermovsky, Kenneth B. Taylor, Henning Birkedal-Hansen, Jeffrey A. Engler

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Mutants in the tissue inhibitor of metalloproteinases-1 (TIMP-1) protein have been created by site-directed mutagenesis and expressed in HeLa cells, using a recombinant vaccinia virus system. Removal of either or both glycosylation sites yielded proteins which retained wild-type inhibitory activity against both human fibroblast-type collagenase (FIB-CL) and M(r) 72 000 gelatinase (GL). However, the double glycosylation mutant protein was expressed at a level that was 2-4-fold lower than that of the wild-type or the single site glycosylation mutants. The 'tiny-TIMP' COOH-terminal deletion mutant that lacks the last 57 residues was also inhibitory, but the dose-response curve suggested that the interaction with the M(r) 72 000 gelatinase had been altered. A number of replacement mutants in the highly conserved NH2-terminal domain, including replacement of P5A and P8A or a double mutation in the VIRAK sequence which is absolutely conserved in all TIMPs in all species (VIRAK to VIAAA), also yielded functional proteins capable of inhibiting FIB-CL and M(r) 72 000 GL and of forming SDS-resistant complexes with FIB-CL. None of the above manipulations abolished inhibitory function suggesting that binding of the inhibitor by the enzyme involves multiple interactions. Copyright (C) 1998 Elsevier Science B.V.

Original languageEnglish (US)
Pages (from-to)21-34
Number of pages14
JournalBiochimica et Biophysica Acta (BBA)/Protein Structure and Molecular
Volume1388
Issue number1
DOIs
StatePublished - Oct 14 1998
Externally publishedYes

Fingerprint

Matrix Metalloproteinase 8
Glycosylation
Gelatinases
Tissue Inhibitor of Metalloproteinase-1
Mutagenesis
Proteins
Vaccinia virus
Enzyme Inhibitors
Mutant Proteins
Site-Directed Mutagenesis
Viruses
HeLa Cells
Mutation

Keywords

  • Collagenase
  • Extracellular matrix
  • M(r) 72 000 Gelatinase

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology
  • Structural Biology

Cite this

Glycosylation and NH2-terminal domain mutants of the tissue inhibitor of metalloproteinases-1 (TIMP-1). / Caterina, Nancy C m; Windsor, L.; Bodden, M. Kirby; Yermovsky, Audra E.; Taylor, Kenneth B.; Birkedal-Hansen, Henning; Engler, Jeffrey A.

In: Biochimica et Biophysica Acta (BBA)/Protein Structure and Molecular, Vol. 1388, No. 1, 14.10.1998, p. 21-34.

Research output: Contribution to journalArticle

Caterina, Nancy C m ; Windsor, L. ; Bodden, M. Kirby ; Yermovsky, Audra E. ; Taylor, Kenneth B. ; Birkedal-Hansen, Henning ; Engler, Jeffrey A. / Glycosylation and NH2-terminal domain mutants of the tissue inhibitor of metalloproteinases-1 (TIMP-1). In: Biochimica et Biophysica Acta (BBA)/Protein Structure and Molecular. 1998 ; Vol. 1388, No. 1. pp. 21-34.
@article{80a5ace54a6941c7b993d2fdd91a5490,
title = "Glycosylation and NH2-terminal domain mutants of the tissue inhibitor of metalloproteinases-1 (TIMP-1)",
abstract = "Mutants in the tissue inhibitor of metalloproteinases-1 (TIMP-1) protein have been created by site-directed mutagenesis and expressed in HeLa cells, using a recombinant vaccinia virus system. Removal of either or both glycosylation sites yielded proteins which retained wild-type inhibitory activity against both human fibroblast-type collagenase (FIB-CL) and M(r) 72 000 gelatinase (GL). However, the double glycosylation mutant protein was expressed at a level that was 2-4-fold lower than that of the wild-type or the single site glycosylation mutants. The 'tiny-TIMP' COOH-terminal deletion mutant that lacks the last 57 residues was also inhibitory, but the dose-response curve suggested that the interaction with the M(r) 72 000 gelatinase had been altered. A number of replacement mutants in the highly conserved NH2-terminal domain, including replacement of P5A and P8A or a double mutation in the VIRAK sequence which is absolutely conserved in all TIMPs in all species (VIRAK to VIAAA), also yielded functional proteins capable of inhibiting FIB-CL and M(r) 72 000 GL and of forming SDS-resistant complexes with FIB-CL. None of the above manipulations abolished inhibitory function suggesting that binding of the inhibitor by the enzyme involves multiple interactions. Copyright (C) 1998 Elsevier Science B.V.",
keywords = "Collagenase, Extracellular matrix, M(r) 72 000 Gelatinase",
author = "Caterina, {Nancy C m} and L. Windsor and Bodden, {M. Kirby} and Yermovsky, {Audra E.} and Taylor, {Kenneth B.} and Henning Birkedal-Hansen and Engler, {Jeffrey A.}",
year = "1998",
month = "10",
day = "14",
doi = "10.1016/S0167-4838(98)00158-7",
language = "English (US)",
volume = "1388",
pages = "21--34",
journal = "Biochimica et Biophysica Acta - Proteins and Proteomics",
issn = "1570-9639",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Glycosylation and NH2-terminal domain mutants of the tissue inhibitor of metalloproteinases-1 (TIMP-1)

AU - Caterina, Nancy C m

AU - Windsor, L.

AU - Bodden, M. Kirby

AU - Yermovsky, Audra E.

AU - Taylor, Kenneth B.

AU - Birkedal-Hansen, Henning

AU - Engler, Jeffrey A.

PY - 1998/10/14

Y1 - 1998/10/14

N2 - Mutants in the tissue inhibitor of metalloproteinases-1 (TIMP-1) protein have been created by site-directed mutagenesis and expressed in HeLa cells, using a recombinant vaccinia virus system. Removal of either or both glycosylation sites yielded proteins which retained wild-type inhibitory activity against both human fibroblast-type collagenase (FIB-CL) and M(r) 72 000 gelatinase (GL). However, the double glycosylation mutant protein was expressed at a level that was 2-4-fold lower than that of the wild-type or the single site glycosylation mutants. The 'tiny-TIMP' COOH-terminal deletion mutant that lacks the last 57 residues was also inhibitory, but the dose-response curve suggested that the interaction with the M(r) 72 000 gelatinase had been altered. A number of replacement mutants in the highly conserved NH2-terminal domain, including replacement of P5A and P8A or a double mutation in the VIRAK sequence which is absolutely conserved in all TIMPs in all species (VIRAK to VIAAA), also yielded functional proteins capable of inhibiting FIB-CL and M(r) 72 000 GL and of forming SDS-resistant complexes with FIB-CL. None of the above manipulations abolished inhibitory function suggesting that binding of the inhibitor by the enzyme involves multiple interactions. Copyright (C) 1998 Elsevier Science B.V.

AB - Mutants in the tissue inhibitor of metalloproteinases-1 (TIMP-1) protein have been created by site-directed mutagenesis and expressed in HeLa cells, using a recombinant vaccinia virus system. Removal of either or both glycosylation sites yielded proteins which retained wild-type inhibitory activity against both human fibroblast-type collagenase (FIB-CL) and M(r) 72 000 gelatinase (GL). However, the double glycosylation mutant protein was expressed at a level that was 2-4-fold lower than that of the wild-type or the single site glycosylation mutants. The 'tiny-TIMP' COOH-terminal deletion mutant that lacks the last 57 residues was also inhibitory, but the dose-response curve suggested that the interaction with the M(r) 72 000 gelatinase had been altered. A number of replacement mutants in the highly conserved NH2-terminal domain, including replacement of P5A and P8A or a double mutation in the VIRAK sequence which is absolutely conserved in all TIMPs in all species (VIRAK to VIAAA), also yielded functional proteins capable of inhibiting FIB-CL and M(r) 72 000 GL and of forming SDS-resistant complexes with FIB-CL. None of the above manipulations abolished inhibitory function suggesting that binding of the inhibitor by the enzyme involves multiple interactions. Copyright (C) 1998 Elsevier Science B.V.

KW - Collagenase

KW - Extracellular matrix

KW - M(r) 72 000 Gelatinase

UR - http://www.scopus.com/inward/record.url?scp=0032517221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032517221&partnerID=8YFLogxK

U2 - 10.1016/S0167-4838(98)00158-7

DO - 10.1016/S0167-4838(98)00158-7

M3 - Article

VL - 1388

SP - 21

EP - 34

JO - Biochimica et Biophysica Acta - Proteins and Proteomics

JF - Biochimica et Biophysica Acta - Proteins and Proteomics

SN - 1570-9639

IS - 1

ER -